PL4036094T3 - Podstawione 4‑fenylopiperydyny, ich wytwarzanie i zastosowanie - Google Patents

Podstawione 4‑fenylopiperydyny, ich wytwarzanie i zastosowanie

Info

Publication number
PL4036094T3
PL4036094T3 PL21217254.8T PL21217254T PL4036094T3 PL 4036094 T3 PL4036094 T3 PL 4036094T3 PL 21217254 T PL21217254 T PL 21217254T PL 4036094 T3 PL4036094 T3 PL 4036094T3
Authority
PL
Poland
Prior art keywords
phenylpiperidines
substituted
preparation
Prior art date
Application number
PL21217254.8T
Other languages
English (en)
Inventor
Konstantin Petrukhin
Rando Allikmets
Graham Johnson
Christopher Cioffi
Emily FREEMAN
Ping Chen
Michael Conlon
Lei Zhu
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Publication of PL4036094T3 publication Critical patent/PL4036094T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL21217254.8T 2014-04-30 2015-04-29 Podstawione 4‑fenylopiperydyny, ich wytwarzanie i zastosowanie PL4036094T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461986578P 2014-04-30 2014-04-30

Publications (1)

Publication Number Publication Date
PL4036094T3 true PL4036094T3 (pl) 2026-04-27

Family

ID=54354744

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21217254.8T PL4036094T3 (pl) 2014-04-30 2015-04-29 Podstawione 4‑fenylopiperydyny, ich wytwarzanie i zastosowanie

Country Status (19)

Country Link
US (8) US9434727B2 (pl)
EP (3) EP3137168B1 (pl)
JP (1) JP6676541B2 (pl)
KR (1) KR102429220B1 (pl)
CN (2) CN111393434B (pl)
AU (1) AU2015253232B2 (pl)
BR (1) BR112016025356B1 (pl)
CA (1) CA2947174C (pl)
DK (2) DK3137168T3 (pl)
ES (2) ES3066710T3 (pl)
FI (1) FI4036094T3 (pl)
HR (1) HRP20260361T1 (pl)
MX (1) MX384244B (pl)
PH (1) PH12016502147B1 (pl)
PL (1) PL4036094T3 (pl)
PT (1) PT4036094T (pl)
SG (1) SG11201608943VA (pl)
SI (1) SI4036094T1 (pl)
WO (1) WO2015168286A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
CN111393434B (zh) 2014-04-30 2022-11-04 哥伦比亚大学董事会 取代的4-苯基哌啶及其制备和用途
GB201604638D0 (en) * 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US11389444B2 (en) 2017-06-15 2022-07-19 Belite Bio, Inc Methods of treating metabolic diseases with fused bicyclic pyrazoles
TWI848911B (zh) 2017-06-15 2024-07-21 美國哥倫比亞大學紐約市信託會 以三唑并吡啶治療rbp4相關疾病之方法
US12440486B2 (en) * 2018-08-01 2025-10-14 The Trustees Of Columbia University In The City Of New York RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout
CN114364382A (zh) * 2019-07-08 2022-04-15 倍亮生物有限责任公司 Rbp4抑制剂的制剂和使用方法
KR102399432B1 (ko) 2020-04-20 2022-05-19 주식회사 엘파니 전도성 고분자 구조체 표면에 코팅된 금속 박막 층을 포함하는, 하이브리드 구조체 및 이의 제조 방법
WO2022139595A1 (en) 2020-12-23 2022-06-30 Xero Limited Transaction data processing systems and methods
CN117440774A (zh) * 2021-05-21 2024-01-23 倍亮生物有限责任公司 年龄相关黄斑变性的生物标记
WO2023097221A1 (en) * 2021-11-23 2023-06-01 Belite Bio, Inc Tablet formulations of rbp4 inhibitors and methods of use
WO2025108420A1 (zh) 2023-11-24 2025-05-30 北京双鹤润创科技有限公司 一种降低rbp4的血清浓度的化合物及用途
WO2025195018A1 (zh) * 2024-03-22 2025-09-25 润尔眼科药物（广州）有限公司 一种苯基哌啶化合物及其应用
WO2025195508A1 (zh) * 2024-03-22 2025-09-25 润尔眼科药物（广州）有限公司 一种苯基杂环化合物及其应用
WO2026018214A1 (en) 2024-07-19 2026-01-22 Tapi Czech Industries S.R.O. Solid state forms of tinlarebant and process for preparation thereof
CN122213077A (zh) * 2024-12-13 2026-06-16 北京京卫燕康生物医药有限公司 一种苯基取代的杂环化合物及其制备方法和应用

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926606A1 (de) 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
DE4130514A1 (de) 1991-09-13 1993-03-18 Chemie Linz Deutschland Verfahren zur herstellung reiner n,n'-unsymmetrisch substituierter phenylharnstoffe
US5532243A (en) 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
US5312814A (en) 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
AU1117497A (en) 1995-11-13 1997-06-05 Albany Medical College Analgesic compounds and uses thereof
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
DE69815090T2 (de) 1997-03-03 2004-02-19 Eisai Co., Ltd. Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
WO1999065867A1 (en) 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
JP2002527051A (ja) 1998-10-09 2002-08-27 メルク エンド カムパニー インコーポレーテッド デルタ６脂肪酸デサチュラーゼ
WO2000042852A1 (en) 1999-01-25 2000-07-27 Smithkline Beecham Corporation Compounds and methods
CA2369822A1 (en) 1999-04-14 2000-10-19 Merck & Co., Inc. Novel human voltage-gated potassium channel
WO2001024786A1 (en) 1999-05-13 2001-04-12 Shionogi & Co., Ltd. Preventive or therapeutic drugs for diabetes
WO2000071511A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
KR20020087041A (ko) 1999-07-28 2002-11-21 아벤티스 파마슈티칼스 프로덕츠 인크. 치환된 옥소아자헤테로사이클릴 화합물
US6372793B1 (en) 1999-08-20 2002-04-16 Florida Agricultural & Mechanical University Method for treatment of a neurological disease characterized by impaired neuromodulator function
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE60124730T2 (de) 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
EP1283897A4 (en) 2000-05-16 2004-08-04 Merck & Co Inc GENE RESPONSIBLE FOR STARGARDT-LIKE, DOMINANT, MAKULA-DYSTROPHY
EP1313477A4 (en) 2000-07-15 2004-03-03 Smithkline Beecham Corp COMPILATIONS AND METHODS
JP2004532234A (ja) 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
EP1406900B1 (en) 2001-07-06 2006-10-04 Neurosearch A/S Novel compounds, their preparation and use
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
WO2003024456A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
AU2002340232A1 (en) 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
JP2005517008A (ja) 2002-02-05 2005-06-09 イーライ・リリー・アンド・カンパニー Ｐｐａｒモジュレーターとして用いるためのウレアリンカー誘導体
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
CA2476583C (en) 2002-03-13 2011-07-05 Kristof Van Emelen Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
WO2003092606A2 (en) 2002-05-01 2003-11-13 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
DK1522314T3 (da) 2002-06-26 2014-05-26 Ono Pharmaceutical Co Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse
US20060100233A1 (en) 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004010942A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7501405B2 (en) * 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
US7700583B2 (en) * 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
WO2004108135A1 (en) 2003-05-30 2004-12-16 Merck & Co., Inc. Composition and method for treating macular disorders
JP2006527756A (ja) 2003-06-19 2006-12-07 ファイザー・プロダクツ・インク Ｎｋ１拮抗薬
FR2857363B1 (fr) * 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20080312189A1 (en) 2004-03-05 2008-12-18 Eisai Co., Ltd. Cadasil Treatment with Cholinesterase Inhibitors
ATE531705T1 (de) 2004-05-18 2011-11-15 Schering Corp Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
EP1779867A4 (en) 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
FR2872416B1 (fr) 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
DE502005003491D1 (de) 2004-08-02 2008-05-08 Sanol Arznei Schwarz Gmbh Carboxamide des indolizins und seiner aza- und diazaderivate
JP2006077006A (ja) 2004-08-13 2006-03-23 Eisai Co Ltd 加齢に伴う過活動膀胱治療薬
AU2005287343A1 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
JP4639696B2 (ja) 2004-08-31 2011-02-23 Ｊｓｒ株式会社 磁性体複合粒子およびその製造方法
JP4958787B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US20060089378A1 (en) 2004-10-27 2006-04-27 Mingde Xia Tetrahydro-pyridinyl pyrazole cannabinoid modulators
WO2006052860A2 (en) 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
EP1817025A2 (en) 2004-11-23 2007-08-15 PTC Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
JP2006176503A (ja) 2004-11-26 2006-07-06 Tohoku Univ 脳血管障害を伴うアルツハイマー病治療薬
EP1930046A1 (en) 2004-12-08 2008-06-11 Sirion Therapeutics, Inc. Retinol binding protein and transthyretin modulators for treating diabetes
EP1838690A2 (en) * 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
GB0503056D0 (en) 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
EP2392328A1 (en) 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
UA81382C2 (en) 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
CN102295636A (zh) * 2005-07-29 2011-12-28 弗·哈夫曼-拉罗切有限公司 吲哚-3-基-羰基-哌啶和哌嗪衍生物
EP1923388A4 (en) 2005-08-12 2011-03-09 Takeda Pharmaceutical BRAIN / NEURONAL CELL PROTECTIVE AGENT AND THERAPEUTIC AGENT FOR SLEEP DISORDERS
JP2009507791A (ja) 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
DE102005049954A1 (de) * 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
WO2007086584A1 (ja) 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
US20070254911A1 (en) 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
KR101077295B1 (ko) 2006-05-18 2011-10-26 에프. 호프만-라 로슈 아게 아데노신 ａ2ｂ 수용체 길항물질로서의 티아졸로-피라미딘/피리딘 우레아 유도체
EP2086973B1 (en) 2006-10-11 2012-01-25 Amgen Inc., Imidazo- and triazolo-pyridine compounds and methods of use therof
MX2009005544A (es) 2006-12-08 2009-06-05 Hoffmann La Roche Indoles.
DE102006060598A1 (de) 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
US8609840B2 (en) 2007-06-21 2013-12-17 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
CN101842098A (zh) 2007-08-10 2010-09-22 基因实验室技术有限公司 用于治疗病毒感染的含氮的二环化学实体
US7973079B2 (en) 2007-09-27 2011-07-05 Revision Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
KR20100097098A (ko) 2007-09-27 2010-09-02 리비젼 쎄러퓨틱스, 인크. 레티놀 관련 질환을 치료하기 위한 방법 및 화합물
EP2202223B1 (en) 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
BRPI0913291A2 (pt) 2008-05-30 2019-01-15 Takeda Pharmaceuticals Co composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
AR073739A1 (es) 2008-09-10 2010-12-01 Kalypsys Inc Aminopirimidinas como inhibidores de los receptores de histamina
WO2010077915A1 (en) 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Novel compounds useful as cc chemokine receptor ligands
CN102282147B (zh) 2009-01-28 2015-09-30 卡拉治疗学股份有限公司 二环吡唑并-杂环
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
JP5642661B2 (ja) 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
TW201041868A (en) 2009-03-20 2010-12-01 Intervet Int Bv Anthelmintic agents and their use
US20120010186A1 (en) 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2758587A1 (en) 2009-04-13 2010-10-21 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
JP5706337B2 (ja) 2009-04-16 2015-04-22 武田薬品工業株式会社 （とりわけ）糖尿病の予防または治療に有用なｎ−アシル−ｎ’−フェニルピペラジンの誘導体
MX2011012584A (es) 2009-05-26 2012-02-21 Exelixis Inc Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación.
US8102887B2 (en) 2009-05-26 2012-01-24 Corning Incorporated Edge bonded optical packages
TW201109327A (en) 2009-05-28 2011-03-16 Otsuka Pharma Co Ltd Heterocyclic compound
DK2477983T3 (en) 2009-09-16 2015-06-29 Univ Edinburgh (4-phenyl-piperidin-1-yl) - [5-1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONFORBINDELSER AND THEIR USE
WO2011059881A1 (en) 2009-11-12 2011-05-19 The Trustees Of Columbia University In The City Of New York Treatment of ophthalmic conditions with fluorenone derivatives
JP5848712B2 (ja) 2009-12-11 2016-01-27 ノノ インコーポレイテッド 虚血性疾患および他の疾患を治療するための薬剤および方法
CA2791738C (en) 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
WO2011116356A2 (en) 2010-03-19 2011-09-22 Sanford-Burnham Medical Research Institute Positive allosteric modulators of group ii mglurs
WO2011116123A1 (en) 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
WO2011149993A2 (en) 2010-05-25 2011-12-01 Abbott Laboratories SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
WO2011156632A2 (en) 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
MX2012015135A (es) * 2010-07-01 2013-05-06 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
BR112013004623A2 (pt) 2010-08-27 2016-07-05 Novartis Ag "inibidores de desacetilases com base em hidroxamato."
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
JP6130827B2 (ja) 2011-05-17 2017-05-17 塩野義製薬株式会社 ヘテロ環化合物
WO2013166040A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York S-fta and s-fta analogues capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular degeneration, stargardt disease, and other retinal disease characterized by excessive lipofuscin accumulation
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9903131B2 (en) 2012-12-22 2018-02-27 Maytronics Ltd. Autonomous pool cleaning robot
TW201501713A (zh) * 2013-03-01 2015-01-16 Kyowa Hakko Kirin Co Ltd 眼炎症性疾病之預防及／或治療劑
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
WO2014160409A1 (en) 2013-03-14 2014-10-02 The Trustees Of Columbia University In The City Of New York Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
CN111393434B (zh) 2014-04-30 2022-11-04 哥伦比亚大学董事会 取代的4-苯基哌啶及其制备和用途

Also Published As

Publication number Publication date
PT4036094T (pt) 2026-03-26
CN111393434B (zh) 2022-11-04
PH12016502147A1 (en) 2017-01-16
NZ726053A (en) 2023-10-27
EP4691465A2 (en) 2026-02-11
ES2909793T3 (es) 2022-05-10
WO2015168286A8 (en) 2016-11-17
CN106794364A (zh) 2017-05-31
WO2015168286A1 (en) 2015-11-05
US20210214360A1 (en) 2021-07-15
EP3137168A4 (en) 2017-12-20
DK3137168T3 (da) 2022-03-21
JP6676541B2 (ja) 2020-04-08
US20180030060A1 (en) 2018-02-01
PH12016502147B1 (en) 2022-03-23
US20190382409A1 (en) 2019-12-19
MX2016014197A (es) 2017-05-03
SI4036094T1 (sl) 2026-05-29
BR112016025356A8 (pt) 2021-07-06
KR102429220B1 (ko) 2022-08-04
MX384244B (es) 2025-03-14
FI4036094T3 (fi) 2026-03-23
EP4036094A1 (en) 2022-08-03
DK4036094T3 (da) 2026-03-23
CA2947174A1 (en) 2015-11-05
AU2015253232B2 (en) 2020-10-01
US10407433B2 (en) 2019-09-10
EP3137168B1 (en) 2022-01-05
SG11201608943VA (en) 2016-11-29
US20250320218A1 (en) 2025-10-16
US20180354957A1 (en) 2018-12-13
BR112016025356A2 (pt) 2017-08-15
CN106794364B (zh) 2019-12-24
US20150315197A1 (en) 2015-11-05
US9434727B2 (en) 2016-09-06
US11649240B2 (en) 2023-05-16
ES3066710T3 (en) 2026-05-14
US9777010B2 (en) 2017-10-03
EP3137168A1 (en) 2017-03-08
US20160368925A1 (en) 2016-12-22
AU2015253232A1 (en) 2016-11-24
EP4691465A3 (en) 2026-03-25
US12404277B2 (en) 2025-09-02
JP2017514822A (ja) 2017-06-08
HK1232169A1 (en) 2018-01-05
US20230312585A1 (en) 2023-10-05
HRP20260361T1 (hr) 2026-04-24
EP4036094B1 (en) 2025-12-24
CA2947174C (en) 2023-02-28
BR112016025356B1 (pt) 2023-04-18
US10072016B2 (en) 2018-09-11
US10913746B2 (en) 2021-02-09
CN111393434A (zh) 2020-07-10
KR20160147037A (ko) 2016-12-21

Similar Documents

Publication Publication Date Title
IL252346A0 (en) Heteroaryl compounds, their preparation and use
IL247713A0 (en) Indazole 3-carboxyamides converted at the 5-position, their preparation and their use
SG11201608943VA (en) Substituted 4-phenylpiperidines, their preparaiton and use
GB201401617D0 (en) Novel combination and use
HUE052575T2 (hu) Új kombináció és alkalmazás
SG11201704473WA (en) New methods and uses
GB201408673D0 (en) Medicaments,uses and methods
PL3166945T3 (pl) Nowe pochodne triazolopirymidynonu lub triazolopirydynonu i ich zastosowanie
GB201416716D0 (en) Use
IL251335A0 (en) Piperidinylpyrazolopyrimidinones and their use
GB201416727D0 (en) Use
IL249122A0 (en) History of imidazole- or 4,2,1-triazole and their use
PT3288575T (pt) Complexo de proteína-melanina bioassimilável, sua preparação e utilizações
RO130539B8 (ro) Compoziţie erbicidă, procedeu de preparare şi utilizarea acesteia
IL249073B (en) Cytin-glucan complex, its preparation and uses
ZA201608621B (en) Silicon-containing azodicarboxamides, their preparation and use
PL3386988T3 (pl) Nowe pochodne dihydropiranopirymidynonu i ich zastosowanie
PL3122184T3 (pl) Mikrokapsułki chlomazonu, ich wytwarzanie i zastosowanie
IL249897A0 (en) 2-oxo-4,3-dihydropyridine-5-carboxylates and their use
IL251930A0 (en) Anylhydroxy derivatives, their preparation and medical uses
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201420365D0 (en) Use
GB201410184D0 (en) Odontalgic preparation